Home · Costs · Medicare GLP-1 Bridge

Medicare GLP-1 Bridge: Who Qualifies and What It Covers

Eligibility, covered drugs and the $50 copay, from Medicare.gov and CMS.

Released: Last reviewed:

Short answer · November 8, 2026

What does the Medicare GLP-1 Bridge cover? The Medicare GLP-1 Bridge lets eligible Part D enrollees get Foundayo, Wegovy or the Zepbound KwikPen for a $50 monthly copay from July 1, 2026 through December 31, 2027, but it covers only those three products for weight management, not Zepbound vials or compounded drugs. Medicare.gov requires a BMI of 35 or more, or 30 or more or 27 or more with listed conditions such as uncontrolled high blood pressure or prediabetes. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible; their Part D plan might cover a GLP-1.

Medicare usually does not pay for drugs used only for weight loss. The GLP-1 Bridge is a temporary CMS program that sits outside the normal Part D benefit: you pay a flat $50 copay at the pharmacy, and the payment does not count toward your deductible or yearly out-of-pocket limit.

Who qualifies and what is covered

Medicare GLP-1 Bridge at a glance (Medicare.gov and CMS pages read October 15, 2026)
ItemWhat the official pages say
DatesJuly 1, 2026 to December 31, 2027 (extended through 2027 per CMS’s BALANCE page, modified September 29, 2026)
Your cost$50 a month for a 28- or 30-day supply, at any income; it does not count toward your Part D deductible or out-of-pocket limit; Extra Help cannot lower it
Covered drugsFoundayo (tablet), Wegovy (injection or tablet), Zepbound KwikPen only. The single-dose Zepbound pen and Zepbound vials are not covered; compounded drugs are not covered
Who qualifiesAge 18+ with Part D (or Medicare Advantage drug coverage) and, when starting therapy: BMI 35+; or BMI 30+ with heart failure with preserved ejection fraction, uncontrolled high blood pressure or chronic kidney disease stage 3a+; or BMI 27+ with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease
Not eligiblePeople with type 2 diabetes, moderate-to-severe obstructive sleep apnea or fatty liver disease (their Part D plan might cover a GLP-1), or whose Part D plan already covers their GLP-1
Plan choiceNo specific Part D plan is required; Open Enrollment runs October 15 to December 7, 2026 for 2027 plans

One phrase on the CMS BALANCE page is worth knowing because it is often misreported: the page answers a question about "the BALANCE Model not launching in Medicare in 2027". The Bridge was extended to collect data ahead of any future Part D change.

Worked examples

  • BMI 36, no diabetes, on Wegovy: eligible; 12 months cost 12 × $50 = $600, against $4,188 a year at NovoCare’s $349 pen price.
  • BMI 33 with uncontrolled high blood pressure, prescribed Zepbound vials: the condition qualifies, but vials do not. Switching to the Zepbound KwikPen is a prescription question for your clinician.
  • Type 2 diabetes: not eligible for the Bridge; check whether your Part D plan covers Ozempic or Mounjaro for diabetes.

If you do not qualify

If you do not qualify: monthly self-pay prices (dated)
RouteMonthly priceSource · date
Zepbound vials or pens, LillyDirect self-pay$299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with each refill within 45 days; otherwise $499 / $699)lilly.com (archived September 30, 2026) · read October 15, 2026
Wegovy pill, NovoCare$149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg)novocare.com · October 15, 2026
Wegovy pen, NovoCare$349; new patients $199 for two fills of 0.25/0.5 mg through December 31, 2026novocare.com · October 15, 2026
Compounded tirzepatide, NexLife$129 month to month; $115 on a 12-month plan (not FDA-approved)nexlife.us · November 6, 2026
Compounded semaglutide, NexLife$109 month to month; $95 on a 12-month plan (not FDA-approved)nexlife.us · November 6, 2026

Compounded semaglutide and tirzepatide are not FDA-approved and are not covered by Medicare. See our costs without insurance, the compounded tirzepatide price comparison and who should not take a GLP-1.

Editor’s pick · 94/100 on our v4.1 methodology

NexLife

$129/mo compounded tirzepatide month to month, $115/mo on a 12-month plan; compounded semaglutide $109/mo, or $95/mo on 12 months. Same price at every dose, no membership (prices as of November 6, 2026).

  • Clinician review and medical guidance (NexLife Medical Group), a GLP-1 nutrition plan, a 1:1 wellness-coach call, 24/7 support, free expedited shipping
  • Plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA)
  • Cancellations take effect after 30 days; compounded drugs are not FDA-approved

FAQ

What does the Medicare GLP-1 Bridge cover?

The Medicare GLP-1 Bridge lets eligible Part D enrollees get Foundayo, Wegovy or the Zepbound KwikPen for a $50 monthly copay from July 1, 2026 through December 31, 2027, but it covers only those three products for weight management, not Zepbound vials or compounded drugs. Medicare.gov requires a BMI of 35 or more, or 30 or more or 27 or more with listed conditions such as uncontrolled high blood pressure or prediabetes. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible; their Part D plan might cover a GLP-1.

Does the $50 count toward my Part D deductible?

No. Medicare.gov says the $50 payment does not count toward your drug plan deductible or yearly out-of-pocket limit, cannot be lowered by Extra Help and cannot be spread over months with the Medicare Prescription Payment Plan. It covers a one-month supply of 28 or 30 days, depending on the drug.

Do I need to change Part D plans during Open Enrollment?

No specific Part D plan is required for the Bridge, but you need Part D or Medicare Advantage drug coverage. Open Enrollment runs October 15 to December 7, 2026, with changes starting January 1, 2027. Compare plans for your other drugs as usual.

Are Zepbound vials covered?

No. Medicare’s fact sheet lists the Zepbound KwikPen only and says the single-dose Zepbound pen and Zepbound vials are not covered. Foundayo tablets and Wegovy injection or tablets are covered for people who meet the eligibility rules.

Can I use the Bridge for compounded semaglutide?

No. The Bridge covers three FDA-approved products only: Foundayo, Wegovy and the Zepbound KwikPen. Compounded semaglutide and tirzepatide are not FDA-approved and are paid in cash.

Sources

  1. Medicare.gov — Weight-loss drugs (GLP-1 Bridge eligibility) (read October 15, 2026)
  2. Medicare.gov — Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month (Product No. 12234, June 2026) (read October 15, 2026)
  3. CMS — Medicare GLP-1 Bridge (page modified July 13, 2026) (read October 15, 2026)
  4. CMS — BALANCE Model (page modified September 29, 2026) (read October 15, 2026)
  5. Lilly LillyDirect — Zepbound self-pay (archived September 30, 2026) (read October 15, 2026)
  6. NovoCare — Wegovy self-pay offer (read October 15, 2026)
  7. NexLife — Compounded tirzepatide plans (prices as of November 6, 2026; plan terms read October 15, 2026)
  8. NexLife — Compounded semaglutide plans (prices as of November 6, 2026; plan terms read October 15, 2026)
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.